CD4+ T lymphocytes: A critical component of antitumor immunity

  • Ostrand-Rosenberg S
  • 9


    Mendeley users who have this article in their library.
  • 69


    Citations of this article.


Both prophylactic and therapeutic vaccines targeting a wide variety of cancers are being developed. Because of the potency of cell-mediated immunity, many vaccine strategies are focused on activating tumor-specific cytotoxic CD8+ T lymphocytes. CD4+ T lymphocytes are a key element in optimal activation of CD8+ T cells and in the maintenance of immune memory, and therefore their activation is critical for cancer vaccine efficacy. This article reviews the mechanisms by which CD4+ T cells facilitate tumor immunity and the vaccine strategies that enhance CD4+ T cell activity.

Author-supplied keywords

  • CD4+T lymphocytes
  • MHC class II
  • Tumor-specific immunity

Get free article suggestions today

Mendeley saves you time finding and organizing research

Sign up here
Already have an account ?Sign in

Find this document


  • Suzanne Ostrand-Rosenberg

Cite this document

Choose a citation style from the tabs below

Save time finding and organizing research with Mendeley

Sign up for free